Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia Syndrome

Lokich, J. J.; Moore, Cheryl G.

doi:10.7326/0003-4819-101-6-798

Cited by 204 publications

(85 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If therapy is interrupted, resolution takes place over 5-14 days with desquamation of the affected skin. This syndrome has been reported to occur both with SL-DOX (Gordon et al, 1995) and with continuous infusion of doxorubicin (Lokich and Moore, 1984). In one series of 36 patients who received long-term, low-dose continuous infusion of doxorubicin (Vogelzang and Ratain, 1985), 15 of 32 patients treated for more than 30 days developed erythrodysaesthesia.…”

Section: Results Patientsmentioning

confidence: 99%

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma

Goebel¹,

Goldstein²,

Goos³

et al. 1996

Br J Cancer

100

View full text Add to dashboard Cite

Summary The utility of current chemotherapeutic regimens in the treatment of AIDS-related Kaposi 44 (18.5%) had stable disease and two (0.8%) had disease progression. SL-DOX was well tolerated: ten patients discontinued therapy because of adverse events, in four cases because of neutropenia. Grade 3 or 4 neutropenia occurred after 281 of 2023 cycles (13.9%) but involved 137 of 240 patients (57.1%) for whom data were available. SL-DOX has substantial activity in AIDS-KS. Best response is typically seen after fewer than three cycles of chemotherapy and in some cases may be prolonged. The most important adverse event is neutropenia, which occurs after a minority of cycles but which may occur in over half of all patients.

show abstract

Section: Results Patientsmentioning

confidence: 99%

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma

Goebel¹,

Goldstein²,

Goos³

et al. 1996

Br J Cancer

100

View full text Add to dashboard Cite

show abstract

“…For example, palmoplantar erythema in all of our patients was because of TEC (spontaneous resolution without treatment) rather than GVHD. Second, recognition of the distribution pattern, that is, beyond the palms and soles, [22][23][24][25][26] allows for a unifying diagnosis rather than a separate diagnosis for each site of involvement. Third, in men, the high incidence of scrotal involvement actually serves as a clue to the diagnosis of TEC, but in the past was often misdiagnosed as candidiasis despite the use of prophylactic anti-fungal medications.…”

Section: Discussionmentioning

confidence: 99%

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant

Parker

Cooper

Seropian

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

I.v. BU plus fludarabine is an effective conditioning regimen for myeloid neoplasias with low treatment-related mortality. At standard doses, cutaneous toxicity has been reported in o5% of cases. As we observed a much higher incidence of cutaneous toxicity in patients who received predominantly pharmacokinetically based doses of BU, we performed a retrospective analysis of 61 patients who received i.v. BU plus fludarabine ( þ / À antithymocyte globulin; ATG) as a conditioning regimen before allogeneic PBSC transplant. Of the 58 evaluable patients, 33 (57%) developed cutaneous toxicity that fell within the spectrum of toxic erythema of chemotherapy (TEC). The median onset of TEC was 22 days and most patients had multiple sites of involvement, with the groin, axillae and palms/soles being the favored sites. In men, scrotal involvement, sometimes severe, was also commonly observed. Initially, allergic reactions to antibiotics, fungal infections and GVHD were also considered until the clinical presentation of TEC became well recognized. In all patients, the skin healed without specific therapy but resolution often required several weeks. This series suggests that TEC is common after BU/fludarabine þ / À ATG and it is important for transplant physicians to recognize, particularly as misdiagnosis could lead to inappropriate treatment.

show abstract

“…All three, however, had biochemical evidence of zinc deficiency which may have been a contributory factor. Mitozantrone has also been implicated as causing onycholysis in two patients on single agent therapy for carcinoma of the breast (Speechley-Dick et al, 1988). In none of these cases was the palmar or plantar skin involved.…”

mentioning

confidence: 99%

“…On withdrawal of epirubicin the skin changes returned to normal over the course of one month. (Lokich, 1984;Vogelzang, 1985). Onycholysis was recently reported as a consequence of chemotherapy, including anthracyclines in three patients (Cunningham et al, 1985).…”

mentioning

confidence: 99%

Anthracycline-induced toxicity affecting palmar and plantar skin

Jones

Crawford²

1989

Br J Cancer

View full text Add to dashboard Cite

We wish to report an adverse effect of frequent administration of anthracycline cytotoxic drugs, affecting both nails and the palmar and plantar skin. Case 1 J.K., a 70-year-old woman, presented with liver metastases from a carcinoma of uncertain origin. She received chemotherapy including doxorubicin (Adriamycin) at a dose of 20mg per square metre per week (36mg weekly), as a bolus. After 5 weeks she developed painful erythema of the palms and soles, which was followed by desquamation at these sites. On withdrawal of the doxorubicin the skin of both areas returned to normal over the next 2 weeks.Case 2 V.C., a 66-year-old woman received epirubicin (Pharmorubicin) as a bolus dose of 40 mg per square metre per week, for granulosa cell carcinoma of the ovary. After 3 weeks she developed painful desquamation of the plantar skin, with loosening and opacity of both the finger and toe nails. On withdrawal of epirubicin the skin changes returned to normal over the course of one month.Case 3 M.W., a 69-year-old lady received a fortnightly bolus of doxorubicin for a metastatic breast carcinoma. She subsequently developed a painful plantar erythema, with desquamation and onycholysis of toe nails. On stopping treatment her feet returned to normal over a period of one month.

show abstract

Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia Syndrome

Cited by 204 publications

References 7 publications

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant

Anthracycline-induced toxicity affecting palmar and plantar skin

Contact Info

Product

Resources

About